C Number:

Study Gender:

PWG Approval Date

PA05: Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged (a)

Test Compound: Decabromodiphenyl Ether CAS Number: 1163-19-5 Date Report Requested: 02/08/2019 Time Report Requested: 10:28:51 Lab: Battelle

C10672-01 Male See web page for date of PWG Approval

PA05: Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged (a)

Test Compound: Decabromodiphenyl Ether

Date Report Requested: 02/08/2019 Time Report Requested: 10:28:51 Lab: Battelle

Male: Core Males								
	Treatment Groups (mg/kg)							
	0	0.1	0.959	9.59	95.9	959		
Disposition Summary Animals Initially In Study Scheduled Sacrifice Early Deaths Survivors	6	6	6	6	6	6		
Scheduled sacrifice, terminal (SD 5) Animals Examined Microscopically	6 6	6	6	6	6	6 6		
ALIMENTARY SYSTEM LIVER	(6)	(0)	(0)	(0)	(0)	(6)		
CARDIOVASCULAR SYSTEM No Tissues/Organs Examined								
ENDOCRINE SYSTEM THYROID GLAND	(6)	(0)	(0)	(0)	(0)	(6)		
GENERAL BODY SYSTEM No Tissues/Organs Examined								
GENITAL SYSTEM No Tissues/Organs Examined								
HEMATOPOIETIC SYSTEM No Tissues/Organs Examined								
INTEGUMENTARY SYSTEM No Tissues/Organs Examined								
LYMPHOID SYSTEM No Tissues/Organs Examined								
MUSCULOSKELETAL SYSTEM No Tissues/Organs Examined								

Study Number: C10672-01 Test Type: TOX Route: Oral Gavage Species/Strain: Rat/Sprague Dawley	PA05: Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged (a) Test Compound: Decabromodiphenyl Ether CAS Number: 1163-19-5				Date Report Requested: 02/08/2019 Time Report Requested: 10:28:51 Lab: Battelle		
		Male: Core Males					
	Treatment Groups (mg/kg)						
	0	0.1	0.959	9.59	95.9	959	
NERVOUS SYSTEM No Tissues/Organs Examined							
RESPIRATORY SYSTEM No Tissues/Organs Examined							
SPECIAL SENSES SYSTEM No Tissues/Organs Examined							
URINARY SYSTEM No Tissues/Organs Examined							
No Systemic Lesions						<u>.</u>	

PA05: Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged (a)

Test Compound: Decabromodiphenyl Ether

CAS Number: 1163-19-5

Date Report Requested: 02/08/2019 Time Report Requested: 10:28:51 Lab: Battelle

Tumor Summary Data for Male Core Males	Treatment Groups (mg/kg)						
	0	0.1	0.959	9.59	95.9	959	
Total Animals with Primary Neoplasms	0	0	0	0	0	0	
Total Primary Neoplasms	0	0	0	0	0	0	
Total Animals with Benign Neoplasms	0	0	0	0	0	0	
Total Benign Neoplasms	0	0	0	0	0	0	
Total Animals with Malignant Neoplasms	0	0	0	0	0	0	
Total Malignant Neoplasms	0	0	0	0	0	0	
Total Animals with Metastatic Neoplasms	0	0	0	0	0	0	
Total Metastatic Neoplasms	0	0	0	0	0	0	
Total Animals with Malignant Neoplasms Uncertain Primary Site	0	0	0	0	0	0	

PA05: Incidence Rates of Neoplastic Lesions with Systemic Lesions Abridged (a)

Test Compound: Decabromodiphenyl Ether CAS Number: 1163-19-5 Date Report Requested: 02/08/2019 Time Report Requested: 10:28:51 Lab: Battelle

LEGEND

Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

Number of animals with observation reported with percent incidence in parentheses

(a) Systemic lesions are included once in the total lesion count regardless of how many times they occurred in a single animal

Phase day range of terminal sacrifice shown in parentheses in disposition summary

SD – Study Day

** END OF REPORT **